While the Grade 1 (Ki-67 ≤ 2% and < 2 mitoses/10 HPF) and Grade 2 (Ki-67 3% to 20% and 2 to 20 mitoses/10 HPF) neuroendocrine tumours (NET) treatment is mainly based on molecular targeted therapy, extrapulmonary neuroendocrine carcinomas (Grade 3: Ki-67 > 20% or > 20 mitoses/10 HPF) [2] are treated with platinum-based chemotherapy [3, 4] extrapolating the data from small cell lung cancer (SCLC). Here, MKI67 is linked to neuroendocrine carcinoma.